Immodulon Therapeutics announce Orphan Drug Designation for IMM-101 in EU in the treatment of pancreatic cancer

LONDON, UK – December 16, 2014 - Immodulon Therapeutics today announced that Orphan designation EU/3/14/1385 was granted by the European Commission for IMM-101, heat-killed Mycobacterium obuense (whole cell) for the treatment of pancreatic cancer.


Click here to view public summary